Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIM AIM ImmunoTech	$8.94 -6.6%	$9.14	$0.06 ▼ $14.93	$6.82M	0.94	566,417 shs	6,085 shs
ENLV Enlivex Therapeutics	$1.16 -3.3%	$1.01	$0.81 ▼ $8.45	$28.33M	0.74	128,315 shs	400 shs
RANI Rani Therapeutics	$0.54 -2.9%	$0.71	$0.46 ▼ $4.19	$30.64M	N/A	825,433 shs	328 shs
SXTC China SXT Pharmaceuticals	$1.71 -0.6%	$1.77	$0.95 ▼ $11.92	$26.96M	1.12	1.19 million shs	1,259 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIM AIM ImmunoTech	0.00%	-3.15%	-2.41%	-27.06%	-76.07%
ENLV Enlivex Therapeutics	0.00%	+10.09%	+24.56%	+23.69%	-15.49%
RANI Rani Therapeutics	0.00%	+10.29%	-1.02%	-56.19%	-85.47%
SXTC China SXT Pharmaceuticals	0.00%	-6.52%	+24.65%	-31.88%	-80.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIM AIM ImmunoTech	1.7168 of 5 stars	3.5	0.0	1.7	1.7	0.0
ENLV Enlivex Therapeutics	3.2948 of 5 stars	3.7	5.0	2.7	0.8	0.6
RANI Rani Therapeutics	2.2091 of 5 stars	3.5	1.0	2.7	1.7	0.6
SXTC China SXT Pharmaceuticals	0.4679 of 5 stars	0.0	3.0	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIM AIM ImmunoTech	3.00	Buy	$275.00	2,976.06% Upside
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	761.33% Upside
RANI Rani Therapeutics	3.00	Buy	$7.33	1,268.16% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AIM, RANI, ENLV, and SXTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	RANI Rani Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$14.00 ➝ $4.00
4/21/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/3/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/3/2025	RANI Rani Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIM AIM ImmunoTech	$146K	46.78	N/A	N/A	$0.20 per share	44.70
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
RANI Rani Therapeutics	$1.03M	29.91	N/A	N/A	$0.06 per share	8.93
SXTC China SXT Pharmaceuticals	$1.93M	14.03	N/A	N/A	$243.66 per share	0.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIM AIM ImmunoTech	-$28.96M	-$24.00	N/A	N/A	N/A	-12,594.21%	-421.73%	-147.54%	N/A
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
RANI Rani Therapeutics	-$30.02M	-$0.99	N/A	N/A	N/A	N/A	-1,258.76%	-80.52%	8/5/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest AIM, RANI, ENLV, and SXTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A
5/13/2025	Q1 2025	RANI Rani Therapeutics	-$0.22	-$0.22	N/A	-$0.22	N/A	$0.20 million
3/31/2025	Q4 2024	ENLV Enlivex Therapeutics	-$0.16	-$0.23	-$0.07	-$0.23	N/A	N/A
3/31/2025	Q4 2024	RANI Rani Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	$1.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIM AIM ImmunoTech	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIM AIM ImmunoTech	0.05	0.75	0.75
ENLV Enlivex Therapeutics	N/A	7.20	7.20
RANI Rani Therapeutics	2.75	0.88	0.88
SXTC China SXT Pharmaceuticals	0.01	1.40	1.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIM AIM ImmunoTech	12.02%
ENLV Enlivex Therapeutics	1.02%
RANI Rani Therapeutics	30.19%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
AIM AIM ImmunoTech	0.02%
ENLV Enlivex Therapeutics	12.28%
RANI Rani Therapeutics	53.30%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIM AIM ImmunoTech	20	764,000	68.74 million	Not Optionable
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
RANI Rani Therapeutics	110	57.48 million	26.84 million	Optionable
SXTC China SXT Pharmaceuticals	90	15.83 million	15.20 million	Not Optionable

AIM, RANI, ENLV, and SXTC Headlines

Recent News About These Companies

China SXT Pharmaceuticals Inc News (SXTC) - Investing.com

June 25, 2025 | investing.com

China SXT Pharmaceuticals Issues 90 Million Shares Following Warrant Exercise

June 16, 2025 | tipranks.com

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.comM

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.comB

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

October 7, 2024 | globenewswire.com

china sxt pharmaceuticals - SXTC

October 3, 2024 | foxbusiness.com

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock, Short Interest Report

October 1, 2024 | benzinga.com

Can China SXT Pharmaceuticals Inc (SXTC) Stock rise from its doldrums?

July 24, 2024 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock creates opportunities due to its volume and complexity

May 21, 2024 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Alphabet Enters a Bull Market: Is It Time to Buy?
By Ryan Hasson | June 14, 2025
View Alphabet Enters a Bull Market: Is It Time to Buy?
Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup
By Gabriel Osorio-Mazilli | June 16, 2025
View Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup
3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
By Nathan Reiff | June 9, 2025
View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
Will Warner Bros. Discovery’s Split Produce Double the Upside?
By Jeffrey Neal Johnson | June 11, 2025
View Will Warner Bros. Discovery’s Split Produce Double the Upside?
QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally
By Leo Miller | June 27, 2025
View QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally

AIM, RANI, ENLV, and SXTC Company Descriptions

AIM ImmunoTech NYSE:AIM

$8.94 -0.63 (-6.58%)

As of 09:30 AM Eastern

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Enlivex Therapeutics NASDAQ:ENLV

$1.16 -0.04 (-3.25%)

As of 09:30 AM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Rani Therapeutics NASDAQ:RANI

$0.54 -0.02 (-2.90%)

As of 09:31 AM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.71 -0.01 (-0.58%)

As of 09:30 AM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time